home / stock / aps:cc / aps:cc news

APS:CC News and Press, Aptose Biosciences Inc. From 05/04/23

Stock Information
Company Name: Aptose Biosciences Inc.
Stock Symbol: APS:CC
Market: TSXC
Website: aptose.com
Menu
APS:CC APS:CC Quote APS:CC Short APS:CC News APS:CC Articles APS:CC Message Board
Get APS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
APS:CC - Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference

SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, Pr...
APS:CC - Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023

SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter end...

APS:CC - Aptose Biosciences

2023-04-12 15:02:41 ET Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide si...

APS:CC - Aptose to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic maligna...
APS:CC - Aptose Biosciences to Participate in Cantor's The Future of Oncology Virtual Symposium

SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating...

APS:CC - Aptose Reports Results for the Fourth Quarter and Full Year 2022

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─ ─ Continu...

APS:CC - Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies...
APS:CC - Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023

SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the fourth quarter a...

APS:CC - Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman,...

APS:CC - Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia

• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial • New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient • Aptose Elucidates Rationale for Tuspetinib’s Superior Safety Profile ...
Previous 10 Next 10